

CLINICAL PATHWAY:

Evaluation and Management of Suspected *Clostridioides Difficile* (*C. difficile*) Infection in pediatric patients with cancer and hematopoietic cell transplantation recipients

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Inclusion Criteria:

Suspected *C. difficile* infection due to:

- (1) Prolonged or worsening diarrhea (at least 4 liquid stools in 24 hours; [Appendix A](#), [Appendix B](#)) **AND**
- (2) Risk factors for *C. difficile* infection (antibiotics in prior 3 months, hospitalization in prior 3 months, immunocompromised patients due to chemotherapy/humoral immunodeficiency/solid organ transplant, chronic inflammatory bowel disease, G-tube or J-tube need, use of acid suppressive therapies – PPI or H2 blockers, or prior *C. difficile* infection)

Exclusion Criteria:

Soft or formed stools ([Appendix A](#)), < 4 liquid stools in 24 hours, no risk factors for *C. difficile* infection

Place on contact precautions. Send *C. difficile* testing **ONLY** if appropriate (see below).

Considerations for testing for *C. difficile*:

- **<1 years of age:** Generally colonized
 - DO NOT test; Treating for *C. difficile* is not indicated
- **1-2 years of age:** High likelihood of colonization
 - Evaluate/empirically treat for other infectious/non-infectious causes before testing for *C. difficile*
 - Add fiber to the formula of tube-fed patients
 - Stop medications associated with diarrhea; Laxatives/stool softeners should be stopped at least 48 hours prior to testing
- **>2 years of age:**
 - Test **ONLY** if patient has not received laxatives or other medications associated with diarrhea (or diarrhea persists after 48 hours of stopping the medication) **AND** if no alternative reason for diarrhea exists.

Confirmed *C. difficile* disease:

Positive C. difficile Ag and Toxin is consistent with infection, and treatment should be initiated/resumed. If only one of either the C. difficile Ag or Toxin are positive, the C. difficile PCR should be ordered and if positive, treatment should be initiated/resumed.
Positive C. difficile PCR and negative C. difficile Ag/Toxin represents colonization (NOT infection) and should NOT be treated.
 Repeat testing of the same episode is NOT recommended.

Initial Disease

(1st episode, or repeat episode >8 weeks from prior episode)

Recurrent Disease

(Repeat episode up to 8 weeks from prior episode)

Non-Severe Disease:

[diarrhea may contain some blood, WBC and Scr normal for age]

- <18 yrs old: **Vancomycin PO:** 10 mg/kg/dose (max 125 mg/dose) QID **OR** **Metronidazole PO** (if vancomycin PO not available): 10 mg/kg/dose (max 500 mg/dose) TID **OR** 7.5 mg/kg/dose (max 500mg/dose) QID x10 days
 - If no improvement within 5-7 days, considered treatment failure. Follow guidelines under Recurrent Disease.

Severe Disease:

[ill-appearing, diarrhea usually bloody, elevated WBC likely due to *C. diff*]

- **Vancomycin PO:** 10 mg/kg/dose (max 125 mg/dose) QID x 14 days
- If no improvement within 5-7 days: consult ID

Fulminant Disease:

[hypotension/shock due to *C. difficile*, Ileus, Megacolon; serum lactate ≥ 5 mmol/L and peripheral WBC $\geq 50,000$ higher rates of mortality]

- **Metronidazole IV:** 10 mg/kg/dose (max 500 mg/dose) q8h **OR** 7.5 mg/kg/dose (max 500 mg/dose) q6h **AND**
- **Vancomycin PO** 10 mg/kg/dose (max 500 mg/dose) QID
- Duration of treatment: 14 days
- Consults:
 - ID
 - GI
 - Consider Surgery

NOTE: Consider discontinuation of proton pump inhibitors/H2 blockers.

Treatment Options:

[See disease severity under Initial Disease for clarification.]

If failure with metronidazole:

- **Vancomycin PO** 10 mg/kg/dose QID (max 125 mg/dose for non-severe disease and severe disease; max 500 mg/dose for fulminant disease) x 14 days

If failure with vancomycin PO:

- Consider alternate cause of diarrhea
- Consult ID
- Begin **Vancomycin:**
 - Vancomycin PO 10 mg/kg/dose (max 125 mg/dose) QID for non-severe/severe disease x 14 days **OR**
 - Vancomycin PO 10 mg/kg/dose (max 500 mg/dose) QID for fulminant disease x 14 days **followed by taper:**
 - Vancomycin PO 10 mg/kg/dose (max 125 mg/dose) BID x 7 days **followed by**
 - Vancomycin 10 mg/kg/dose (max 125 mg/dose) once daily x 7 days **followed by**
 - Vancomycin 10 mg/kg/dose (max 125 mg) every 2-3 days x 2-8 weeks as directed by ID

If failure with vancomycin taper:

- Consider alternate cause of diarrhea
- Consult ID
- Consider **Fidaxomicin** 16 mg/kg/dose BID for children 6 months to 5 years and 200 mg/dose BID for children 6 years and older. X 10 days; if using Fidaxomicin, please contact Antimicrobial Stewardship Program for up-to-date dosing recommendations.

NOTE: Consider discontinuation of proton pump inhibitors/H2 blockers.

Discharge Criteria: clinically stable, cleared by ID and GI (and surgery, if involved), medication available prior to discharge

Discharge Instructions: Ensure insurance coverage/medication availability prior to discharge, follow up with PCP and/or GI (if involved in hospitalization)

CONTACTS: Tamara MacDonald, PharmD | Jeannette Comeau, MD, Bruce Crooks, MD, Jenny Curran PharmD, Angela Thomas RN.

LAST UPDATED: May 29, 2025

IWK Hematology/Oncology




CLINICAL PATHWAY:

Evaluation and Management of Suspected *Clostridioides Difficile* (*C. difficile*) Infection in pediatric patients with cancer and hematopoietic cell transplantation recipients

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Appendix A: Nursing Flowchart for Appropriate *C. difficile* testing



CONTACTS: Tamara MacDonald, PharmD | Jeannette Comeau, MD, Bruce Crooks, MD, Jenny Curran PharmD, Angela Thomas RN.

LAST UPDATED: May 29, 2025

IWK Hematology/Oncology

CLINICAL PATHWAY:

Evaluation and Management of Suspected *Clostridioides Difficile* (*C. difficile*) Infection in pediatric patients with cancer and hematopoietic cell transplantation recipients

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Appendix B: Provider Flowchart for Appropriate *C. difficile* testing

